A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients

NCT02608437 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma

Interventions

DRUG: SGI-110
DRUG: Ipilimumab

Sponsor

Italian Network for Tumor Biotherapy Foundation

Collaborators

[object Object]